<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124455">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02007473</url>
  </required_header>
  <id_info>
    <org_study_id>1974/MCP</org_study_id>
    <nct_id>NCT02007473</nct_id>
  </id_info>
  <brief_title>A Prospective Non-interventional Study to Evaluate the Safety of Methylene Blue Plasma</brief_title>
  <official_title>A Prospective Non-interventional Study to Evaluate the Safety of Methylene Blue Plasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maco Productions S.A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SynteractHCR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maco Productions S.A.S.</source>
  <oversight_info>
    <authority>United Kingdom: National Health Service</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Greece: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this non-interventional study is to gather data on adverse reactions
      occurring with Methylene Blue plasma administered in a routine clinical practice
      environment; to know more about their characteristics and behaviour and the possible factors
      that may influence their presentation and evolution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multi-centre, non-controlled, non-randomized, non-interventional
      study to evaluate the safety of Methylene Blue (MB) plasma. One centre per country will
      participate from United Kingdom, Belgium, Greece and Spain.

      The haemovigilance Case Report Form (CRF) will be completed for all patients who receive a
      Methylene Blue plasma transfusion and experience an adverse reaction. The patients will be
      monitored for the occurrence of possible adverse reactions within 24 hours after start of
      the transfusion. If the patient experiences an adverse reaction, information about the
      adverse reaction will be documented. Serious adverse reactions will be collected within a
      7-day period after the transfusion.

      Each adverse reaction or serious adverse reaction will be followed up for 28 days after the
      occurrence of the reaction.

      Each centre will provide the number of transfused Methylene Blue plasma units and the number
      of transfused Methylene Blue plasma patients every three months.

      Information collected on the haemovigilance CRF will include:

        -  Details about the transfusion (transfused units, volume, other non-plasma blood
           components transfused)

        -  Details about the plasma (collected from whole blood, aphaeresis or both, filter using,
           type of reference used, illumination device model)

        -  Demographic data

        -  Transfusion history (including hospital department)

        -  History of previous transfusion reactions

        -  Details about the adverse reaction (date and time of reaction)

        -  Signs and symptoms and allocation to a diagnosis

        -  Classification of the adverse reaction (severity, imputability, non-serious or serious)

        -  Actions taken

        -  Outcome

        -  Time to recovery
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The incidence of transfusion reactions following administration of Methylene Blue Plasma based on the total number of transfusions administered</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of specific transfusion reactions following administration of Methylene Blue plasma</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The rate of the different type of adverse events registered along the time frame.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Relationship between transfusion reaction types and indication, gender, age and severity</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Analysis of factors that could be related to transfusion reactions</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Adverse Effects in the Therapeutic Use of Plasma Substitutes</condition>
  <arm_group>
    <arm_group_label>Patients requiring transfusion with plasma</arm_group_label>
    <description>Recipients, who have received a transfusion with Methylene Blue plasma produced using the THERAFLEX MB-Plasma procedure from MacoPharma.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients requiring plasma transfusion
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, who have received a transfusion with Methylene Blue plasma produced using
             the THERAFLEX MB-Plasma procedure from MacoPharma and experience an adverse reaction.

        Exclusion Criteria:

          -  Patients receiving transfusion with other plasma types during the same transfusion
             episode
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hafiz Qureshi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals, Leicester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mercedes Villamayor, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario de Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucien Noens, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Gent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aggeliki Megalou, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>G. H. A. Evaggelismos, Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yamina Bachiri-Rahal</last_name>
    <phone>+33 1 55 90 57 10</phone>
    <email>yamina.bachiri-rahal@synteractHCR.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Herembert</last_name>
    <phone>+33 1 55 90 57 10</phone>
    <email>anne.herembert@synteractHCR.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucien Noens, MD, PhD</last_name>
      <email>Lucien.Noens@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Lucien Noens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>G. H. A. Evaggelismos</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aggeliki Megalou, MD, PhD</last_name>
      <phone>210-7201314</phone>
    </contact>
    <investigator>
      <last_name>Aggeliki Megalou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Villamayor, MD, PhD</last_name>
      <email>mercedes.villamayor.alvarez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Mercedes Villamayor, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hafiz R Qureshi, MD PhD</last_name>
      <email>hafiz.qureshi@uhl-tr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Hafiz R Qureshi, Md PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Greece</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>November 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemovigilance</keyword>
  <keyword>Plasma</keyword>
  <keyword>Pathogen reduction</keyword>
  <keyword>Methylene Blue</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
